In today’s recent session, 1.27 million shares of the Unity Biotechnology Inc (NASDAQ:UBX) have been traded, and its beta is 1.08. Most recently the company’s share price was $1.19, and it changed around -$0.64 or -34.79% from the last close, which brings the market valuation of the company to $20.07M. UBX at last check was trading at a discount to its 52-week high of $3.10, offering almost -160.5% off that amount. The share price’s 52-week low was $0.94, which indicates that the recent value has risen by an impressive 21.01% since then. We note from Unity Biotechnology Inc’s average daily trading volume that its 10-day average is 99320.0 shares, with the 3-month average coming to 246.12K.
Unity Biotechnology Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 3 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended UBX as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. Unity Biotechnology Inc is expected to report earnings per share of -0.4 for the current quarter.
Unity Biotechnology Inc (NASDAQ:UBX) trade information
Instantly UBX has been showing red trend so far today with a performance of -34.79% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.8500 on recent trading dayincreased the stock’s daily price by 35.68%. The company’s shares are currently up 21.88% year-to-date, but still down -32.00% over the last five days. On the other hand, Unity Biotechnology Inc (NASDAQ:UBX) is -38.66% down in the 30-day period. We can see from the shorts that 0.55 million shares have been sold at a short interest cover period of 3.47 day(s).
Unity Biotechnology Inc (UBX) estimates and forecasts
Forecasts for the next quarter put sales growth at 0.00%. Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 39.36%. Unity Biotechnology Inc earnings are expected to increase by 27.87% in 2025, but the outlook is positive 35.74% per year for the next five years.
Unity Biotechnology Inc (NASDAQ:UBX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.31% of Unity Biotechnology Inc shares, and 19.58% of them are in the hands of institutional investors. The stock currently has a share float of 19.84%.
Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund were the top two Mutual Funds as of Dec 31, 2024. The former held 395.99 shares worth $0.48 million, making up 2.35% of all outstanding shares. On the other hand, Vanguard Extended Market Index Fund held roughly 194.78 shares worth around $0.24 million, which represents about 1.15% of the total shares outstanding.
